Transom Taps Luke Dauch to Drive Healthcare M&A Expansion

Transom Capital Group, the Los Angeles-based private equity firm with $1.5 billion under management, has hired Luke Dauch as Business Development Principal — a move signaling the firm's intent to deepen its healthcare services deal pipeline as competition for quality assets intensifies.

Dauch arrives with 22 years in transaction advisory, most recently at Arthur Andersen LLP and KPMG, where he spent two decades structuring deals in healthcare, business services, and software. He'll focus on sourcing and evaluating investment opportunities across Transom's core sectors, with particular emphasis on healthcare services — a category that's seen north of 600 PE-backed transactions annually since 2023.

The hire comes as middle-market PE firms face a dual challenge: dry powder hitting record highs while quality deal flow remains constrained. Transom's answer? Bring in someone who's spent two decades on the other side of the table.

"Luke's extensive transaction experience and deep sector knowledge make him an invaluable addition," said Transom Managing Partner Blake Bartlett in the announcement. What Bartlett didn't say, but what the hire implies: Transom is betting that proprietary deal sourcing — not competitive auctions — will define success in the current environment.

Transom has long played in healthcare, but the firm's recent portfolio moves suggest a shift toward services-heavy businesses rather than pure product or device plays. That's consistent with broader market dynamics: healthcare services companies — think revenue cycle management, behavioral health platforms, specialty staffing — have outperformed on EBITDA multiples and exit velocity compared to their capital-intensive counterparts.

Dauch's background fits the thesis. At KPMG and Arthur Andersen, he advised on transactions spanning physician practice roll-ups, ambulatory surgery center consolidations, and healthcare IT carve-outs. These aren't megadeals — they're the $50M to $300M enterprise value transactions that Transom targets in its lower-mid-market and mid-market strategies.

The timing matters. Regulatory tailwinds — particularly around value-based care reimbursement and Medicare Advantage growth — are creating pockets of fragmentation ripe for consolidation. But those opportunities don't show up in broad auction processes. They require someone who knows where to look and who to call.

That's the role Dauch is stepping into. According to the firm, he'll work alongside Transom's investment team to "identify and assess new opportunities" — which in PE parlance means building a proprietary pipeline before deals hit the market.

Transom Capital manages approximately $1.5 billion across its funds, with a stated focus on lower-mid-market and mid-market companies in business services, healthcare services, software, and value-added distribution. The firm typically targets companies with $10 million to $50 million in EBITDA — a size range where operational improvements and buy-and-build strategies can drive meaningful multiple expansion.

The firm has been active. Recent disclosed investments include healthcare staffing platforms, software-enabled service providers, and niche industrial services businesses. The common thread: fragmented markets with clear consolidation opportunities and predictable cash flows.

But deal volume alone doesn't differentiate in today's market. What matters is sourcing quality. And that's where Dauch's hire becomes strategic rather than simply additive.

Consider the math: PitchBook data shows that proprietary deals — those sourced directly rather than through intermediaries — consistently outperform on entry multiples and IRR. The gap has widened as auction processes have become more efficient (read: more expensive). A firm that can consistently source off-market deals has a structural advantage.

Transom's bet is that Dauch can help shift more of its deal flow into that first category. That requires relationships, sector expertise, and the kind of pattern recognition that only comes from decades of transaction work.

Dauch's resume reads like a case study in transaction advisory depth. Two decades at KPMG and Arthur Andersen means he's seen hundreds of deals from the inside — quality of earnings reports, working capital adjustments, carve-out mechanics, integration planning. That's the kind of operational fluency that helps a BD principal separate real opportunities from well-packaged mediocrity.

Transom hasn't publicly disclosed its current fund's deployment pace, but industry context suggests urgency. Middle-market PE funds raised in 2021-2022 are entering their third and fourth years — the period when investment pace typically accelerates to meet deployment timelines.

At the same time, exit markets remain choppy. Strategic buyers are cautious. IPO windows are unreliable. Secondary buyers are disciplined. That puts a premium on entry execution — buying well matters more than ever when exit multiples are uncertain.

Dauch's role addresses both challenges. Better sourcing means better entry multiples. His transaction structuring background means cleaner deals with fewer post-close surprises. And his healthcare sector focus aligns with one of the few areas where strategic and financial buyers remain consistently active.

The firm's statement emphasized Dauch's ability to "identify high-potential investment opportunities." In practice, that likely means building a network of intermediaries, industry operators, and company founders who'll bring opportunities to Transom before they hit the broader market.

It's worth noting what this hire isn't: Dauch isn't joining as an operating partner focused on portfolio company value creation. He's not a sector head building out a dedicated healthcare vertical. He's business development — the front end of the deal machine. That suggests Transom believes its current challenge is sourcing, not execution.

Transom operates in a crowded field. The lower-mid-market and mid-market healthcare services space is thick with PE firms — from established players like Welsh Carson and Francisco Partners to newer entrants and growth equity shops moving downstream. Differentiation is hard.

That crowding has consequences. Purchase price multiples for quality healthcare services assets have compressed slightly from 2021-2022 peaks, but they remain elevated relative to historical norms. A well-run behavioral health platform or specialty pharmacy services business can still command 10x+ EBITDA in a competitive process.

The real test of this hire won't be visible for 12-18 months. That's how long it takes for a new BD hire to build pipeline, convert relationships into actionable opportunities, and close initial deals. What the market will watch:

Does Transom's deal velocity in healthcare services pick up? If Dauch is effective, the firm should announce more platform investments and add-ons in that sector over the next two years.

Do those deals come through proprietary channels or competitive processes? If Dauch is truly moving the needle, a higher percentage of Transom's healthcare deals should be sourced directly rather than through bankers.

How do entry multiples trend? This is the hardest to track from the outside, but any disclosed deal metrics will signal whether the sourcing strategy is translating into valuation discipline.

Transom's decision to hire a dedicated business development principal — rather than simply adding another investment professional — reflects a strategic choice about where value creation happens in today's market. It's a bet that the biggest bottleneck isn't capital, analytical horsepower, or operational expertise. It's access to the right deals.

That's a departure from the traditional PE model, where junior investment professionals source deals as part of broader responsibilities and senior partners close based on relationships. By creating a dedicated BD role, Transom is acknowledging that sourcing now requires specialized focus and expertise.

While healthcare services remains a favored PE sector, it's not without headwinds. Reimbursement pressure from payers, regulatory uncertainty around corporate practice of medicine, and labor cost inflation are all live issues. The best operators are navigating these successfully, but they're real constraints on margin expansion.

Dauch's transaction background means he's seen these dynamics play out in diligence. The question is whether that pattern recognition translates into better investment selection — identifying companies with genuine competitive moats rather than those riding temporary tailwinds.

Transom's portfolio will provide the answer. If the firm's healthcare investments over the next 18 months cluster around high-margin, asset-light service models with recurring revenue, it'll suggest Dauch is applying a clear investment filter. If they're scattered across subsectors with inconsistent economics, it'll raise questions about whether the sourcing advantage is translating into disciplined capital deployment.

For now, the hire signals intent. Transom sees healthcare services as a priority. It believes proprietary deal flow will drive outperformance. And it's willing to invest in specialized talent to make that happen.

The healthcare services M&A market is entering a period of bifurcation. Top-quartile assets — those with defensible market positions, strong management teams, and clear growth pathways — continue to attract premium valuations and competitive processes. Everything else is facing a reset.

That bifurcation creates opportunity for firms with strong sourcing capabilities. The best deals often don't need to go to market. Founders and management teams with options increasingly prefer negotiated sales to avoid auction fatigue and valuation risk.

Dauch's ability to navigate these subsector dynamics — understanding which valuations reflect genuine quality vs. market hype — will determine whether this hire generates returns or just activity.

Transom declined to provide specifics on Dauch's compensation structure, pipeline targets, or sector priorities beyond the broad healthcare and business services mandate. That's standard for BD hires. The results will speak louder than the press release.

Here's the tension Transom and its peers face: if every middle-market PE firm responds to deal scarcity by hiring dedicated business development talent, does anyone gain an advantage? Or does it just shift the competition from auctions to relationship-building?

The answer probably depends on execution quality. Not all BD hires are created equal. Some bring genuine networks and sector expertise. Others bring Big Four credentials but limited deal generation ability. Dauch's track record will determine which category he falls into.

What's clear is that Transom sees sourcing as a competitive battleground worth investing in. Whether that investment pays off will depend on deal flow, entry multiples, and ultimately, exits. The first two are knowable within 18 months. The last one might take five years.

For now, the market has one more signal that proprietary deal sourcing has become table stakes in middle-market PE. And one more firm betting that the right hire can shift the odds.

Will Transom expand its BD function beyond Dauch, or is this a test case? If the role proves effective, expect more hires. If it doesn't, this could be a one-off experiment.

How does Dauch's sourcing integrate with Transom's existing deal team? The best BD functions operate as extensions of the investment team, not parallel tracks. Cultural fit and process alignment matter as much as individual capability.

And the biggest unknown: can anyone really source their way out of a compressed return environment? Or is this another case of doing more of what worked in the past, even as the market fundamentals shift underneath?

Transom's betting on the former. The next 18 months will show if they're right.